×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen at AHA Scientific Sessions 2014

Amgen will present 13 abstracts at the American Heart Association (AHA) Scientific Sessions 2014, taking place in Chicago November 15-19, 2014.

Follow Amgen on Twitter at http://twitter.com/amgen to receive news updates during AHA.


Nov. 18, 2014 Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels
Nov. 12, 2014 Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions
Nov. 12, 2014 Amgen to Highlight New Data for Investigational Cholesterol-Lowering Medication Evolocumab